Journal Mobile Options
Table of Contents
Vol. 27, No. 5, 2009
Issue release date: June 2009
Dement Geriatr Cogn Disord 2009;27:465–473

Population Variation in Glial Fibrillary Acidic Protein Levels in Brain Ageing: Relationship to Alzheimer-Type Pathology and Dementia

Wharton S.B. · O’Callaghan J.P. · Savva G.M. · Nicoll J.A.R. · Matthews F. · Simpson J.E. · Forster G. · Shaw P.J. · Brayne C. · Ince P.G.
aCenters for Disease Control and Prevention-NIOSH, Morgantown, W.Va., USA; bAcademic Unit of Pathology and cAcademic Unit of Neurology, University of Sheffield, Sheffield, dDepartment of Public Health and Primary Care and eMRC Biostatistics Unit, Institute of Public Health, University of Cambridge, Cambridge, and fDivision of Clinical Neurosciences, University of Southampton, Southampton, UK

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: The cellular pathology of astrocytes in brain ageing and their role in modulating the brain’s response to neurodegenerative pathology remain incompletely understood. Methods: Using quantitative ELISA, we have investigated glial fibrillary acidic protein (GFAP) expression in the population-based neuropathology cohort of the Medical Research Council Cognitive Function and Ageing Study to determine: (1) the population variation in the astroglial hypertrophic response, (2) its relationship to the presence of Alzheimer-type pathology, and (3) its association with cognition. Results: Increasing GFAP was found with increasing Braak stage, levels increasing even at early stages. Within Braak stages, GFAP did not differ between demented and non-demented individuals, but there was greater variance in GFAP in the demented. Possession of ApoE ε4 was associated with slightly increased GFAP levels (not significant) for given amyloid β protein loads. Conclusion: In a population-based sample, increasing gliosis precedes development of Alzheimer lesions. Population variation in GFAP with varying Alzheimer lesion burdens suggests that they are not the only driver for astrogliosis. GFAP was not independently predictive of dementia, but the variation in astrocytic responses may be a factor modulating brain responses to neurodegenerative pathology.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Hardy J, Selkoe D: The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297:353–356.
  2. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC-CFAS): Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169–175.
  3. Maragakis N, Rothstein J: Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2006;2:679–689.
  4. Vehmas A, Kawas C, Stewart W, Troncoso J: Immune reactive cells in senile plaques and cognitive decline in Alzheimer’s disease. Neurobiol Aging 2003;24:321–331.
  5. Nagele R, Wegiel J, Venkataraman V, Iamki H, Wang KC, Wegiel J: Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease. Neurobiol Aging 2004;25:663–674.
  6. Oide T, Kinoshita T, Arima K: Regression of senile plaques in the natural course of Alzheimer’s disease. Neuropathol Appl Neurobiol 2006;32:539–556.
  7. Meda L, Baron P, Scarlato G: Glial activation in Alzheimer’s disease: the role of Aβ and its associated proteins. Neurobiol Aging 2001;22:885–893.
  8. Abramov A, Canevari L, Duchen M: Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid toxicity. J Neurosci 2003;23:5088–5095.
  9. Mrak R, Griffin W: Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 2005;26:349–354.
  10. Wyss-Coray T, Loike J, Brionne T, Lu E, Anankov R, Yan F, Silverstein S, Husemann J: Adult mouse astrocytes degrade amyloid-Aβ in vitro and in situ. Nat Med 2003;9:453–457.
  11. Volterra A, Meldolesi J: Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci 2005;6:626–640.
  12. Pekny M, Nilsson M: Astrocyte activation and reactive gliosis. Glia 2005;50:427–434.
  13. Jing R, Wilhelmsson U, Goodwill W, Li L, Pan Y, Pekny M, Skalli O: Synemin is expressed in reactive astrocytes in neurotrauma and interacts differentially with vimentin and GFAP intermediate filament networks. J Cell Sci 2007;120:1267–1277.
  14. Morgan T, Rozovsky I, Goldsmith S, Stone D, Yoshida T, Finch C: Increased transcription of the astrocyte gene GFAP during middle-age is attenuated by food restriction: implications for the role of oxidative stress. Free Radic Biol Med 1997;23:524–528.
  15. Ingelsson M, Fukomoto H, Newell K, Growdon J, Hedley-Whyte E, Frosch M, Albert M, Hyman B, Irizarry M: Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004;62:925–931.
  16. Kashon M, Ross G, O’Callaghan J, Miller D, Petrovitch H, Burchfield C, Sharp D, Markesbery W, Davies D, Hardman J, Nelson J, White L: Associations of cortical astrogliosis with cognitive performance and dementia status. J Alzheimers Dis 2004;6:595–604.
  17. Simpson J, Ince P, Lace G, Forster G, Shaw P, Matthews F, Savva G, Brayne C, Wharton S; on behalf of the MRC Cognitive Function and Ageing Neuropathology Study Group: Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol Aging 2008, E-pub ahead of print.
  18. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC-CFAS): Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA study. Psychol Med 1998;28:319–335.
  19. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259.
  20. McLendon R, Bigner D: Immunohistochemistry of the glial fibrillary acidic protein: basic and applied considerations. Brain Pathol 1994;2:221–228.

    External Resources

  21. Ross G, O’Callaghan J, Sharp D, Petrovich H, Miller D, Abbott R, Nelson J, Launer L, Foley D, Burchfield C, Hardman J, White L: Quantification of regional glial fibrillary acidic protein levels in Alzheimer’s disease. Acta Neurol Scand 2003;107:318–323.
  22. Mirra S, Heyman A, McKeel D, Sumi S, Crain B, Brownlee L, Vogel F, Hughes J, Van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). 2. Standardisation of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991;41:479–486.
  23. Braak H, Alafuzoff I, Arzberger T, Kretaschmar H, del Tredici K: Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006;112:389–404.
  24. O’Callaghan J: Quantification of glial fibrillary acidic protein: comparison of slot-immunobinding assays with a novel sandwich ELISA. Neurotoxicol Teratol 1991;13:275–281.
  25. O’Callaghan J: Measurement of glial fibrillary acidic protein; in Costa L (ed): Current Protocols in Toxicology. New York, Wiley, 2002, pp 12.81.11–12.81.12.
  26. Nicoll J, Burnett C, Love S, Graham D, Dewar D, Ironside J, Stewart J, Vinters H: High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol 1997;41:716–721.
  27. Wenham P, Price W, Blandell G: Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158–1159.
  28. Laping N, Teter B, Nichols N, Rozovsky I, Finch C: Glial fibrillary acidic protein: regulation by hormones, cytokines, and growth factors. Brain Pathol 1994;4:259–275.
  29. Vinters H, Kleinschmidt-Demasters B: General pathology of the central nervous system; in Love S, Louis D, Ellison D (eds): Greenfield’s Neuropathology. London, Hodder Arnold, 2008, pp 8–22.
  30. Nichols N, Day J, Laping N, Johnson S, Finch C: GFAP mRNA increases with age in rat and human brain. Neurobiol Aging 1993;14:421–429.
  31. Sheng J, Mrak R, Rovnaghi C, Kozlowska E, Van Eldik L, Griffin W: Human brain S100β and S100β mRNA expression increases with age: pathogenic implications for Alzheimer’s disease. Neurobiol Aging 1996;17:359–363.
  32. Wu Y, Zhang AQ, Yew DT: Age related changes of various markers of astrocytes in senescence-accelerated mice hippocampus. Neurochem Int 2005;46:565–574.
  33. Roelofs R, Fischer D, Houtman S, Sluijs J, Van Haren W, Van Leeuwen F, Hol E: Adult human subventricular, subgranular, and subpial zones contain astrocytes with a specialized intermediate filament cytoskeleton. Glia 2005;52:289–300.
  34. Nielsen A, Holm I, Johansen M, Bonven B, Jorgensen P, Jorgensen A: A new splice variant of glial fibrillary acidic protein, GFAPε, interacts with the presenilin proteins. J Biol Chem 2002;277:29983–29991.
  35. Blechinberg J, Holm I, Nielsen K, Jensen T, Jorgensen A, Nielsen A: Identification and characterization of GFAPκ, a novel glial fibrillary acidic protein isoform. Glia 2007;55:497–507.
  36. Mouser P, Head E, Ha KH, Rohn T: Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer’s disease brain. Am J Pathol 2006;168:936–946.
  37. Moossy J, Zubenko G, Martinez A, Rao G: Bilateral symmetry of morphologic lesions in Alzheimer’s disease. Arch Neurol 1988;45:251–254.
  38. Mander P, Borutaite V, Moncada S, Brown G: Nitiric oxide from inflammatory-activated glia synergizes with hypoxia to induce neuronal death. J Neurosci Res 2004;79:208–215.

    External Resources

  39. Kobayashi K, Hayashi M, Nakano H, Shimazaki M, Sugimori K, Koshino Y: Correlation between astrocyte apoptosis and Alzheimer changes in gray matter lesions in Alzheimer’s disease. J Alzheimers Dis 2004;6:623–632.
  40. O’Callaghan J, Sriram K: Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin Drug Saf 2005;4:433–442.
  41. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj E, Jones P, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood C, Petersen R, Smith M: Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001;60:759–767.
  42. Sheng J, Mrak R, Griffin W: Enlarged and phagocytic, but not primed, interleukin-1α-immunoreactive microglia increase with age in normal brain. Acta Neuropathol 1998;95:229–234.
  43. Von Zglinicki T, Saretzki G, Ladhoff J, d’Adda di Fagagna F, Jackson S: Human cell senescence as a DNA damage response. Mech Ageing Dev 2005;126:111–117.
  44. Herrmann J, Imura T, Song B, Qi J, Ao Y, Nguyen T, Korsak R, Takeda K, Akira S, Sofroniew M: STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J Neurosci 2008;28:7231–7243.
  45. Correa-Cerro L, Mandell J: Molecular mechanisms of astrogliosis: new approaches with mouse genetics. J Neuropathol Exp Neurol 2007;66:169–176.
  46. Lepore A, Dejea C, Carmen J, Rauck B, Kerr D, Sofroniew M, Maragakis N: Selective ablation of proliferating astrocytes does not affect disease outcome in either acute or chronic models of motor neuron degeneration. Exp Neurol 2008;211:423–432.
  47. Lovatt D, Sonnewald U, Waagepetersen H, Schousboe A, He W, Lin JC, Han X, Takano T, Wang S, Sim F, Goldman S, Nedergaard M: The transcriptome and metabolic gene signature of protoplasmic astrocytes in the adult murine cortex. J Neurosci 2007;27:12255–12266.
  48. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales K, Paul S: Apolipoprotein E promotes astrocyte colocalisation and degradation of deposited amyloid-β peptides. Nat Med 2004;10:719–726.
  49. Wyss-Coray T: Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006;12:1005–1015.
  50. Alafuzoff I, Overmyer M, Helisalmi S, Soininen H: Lower counts of astroglia and activated microglia in patients with Alzheimer’s disease with regular use of non-steroidal anti-inflammatory drugs. J Alzheimers Dis 2000;2:37–46.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50